1. Home
  2. ADSK vs ARGX Comparison

ADSK vs ARGX Comparison

Compare ADSK & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Autodesk Inc.

ADSK

Autodesk Inc.

HOLD

Current Price

$252.72

Market Cap

47.8B

Sector

Technology

ML Signal

HOLD

Logo argenx SE

ARGX

argenx SE

HOLD

Current Price

$749.88

Market Cap

52.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADSK
ARGX
Founded
1982
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
47.8B
52.0B
IPO Year
1994
2017

Fundamental Metrics

Financial Performance
Metric
ADSK
ARGX
Price
$252.72
$749.88
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
26
19
Target Price
$338.27
$991.56
AVG Volume (30 Days)
2.3M
330.3K
Earning Date
05-28-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
22.20
N/A
EPS
3.76
N/A
Revenue
$6,131,000,000.00
N/A
Revenue This Year
$12.75
$40.56
Revenue Next Year
$10.24
$21.30
P/E Ratio
$65.77
$33.69
Revenue Growth
11.53
N/A
52 Week Low
$215.01
$510.06
52 Week High
$329.09
$934.62

Technical Indicators

Market Signals
Indicator
ADSK
ARGX
Relative Strength Index (RSI) 56.75 29.81
Support Level $252.55 $698.92
Resistance Level $303.16 $779.00
Average True Range (ATR) 9.18 20.73
MACD 4.34 -9.91
Stochastic Oscillator 95.03 3.99

Price Performance

Historical Comparison
ADSK
ARGX

About ADSK Autodesk Inc.

Founded in 1982, Autodesk is a multinational software company best known for pioneering computer-aided design, or CAD, with its AutoCAD product. Nowadays, Autodesk provides design software for a variety of verticals, including architecture & construction, manufacturing, and media & entertainment. Autodesk products have been used in some of the world's most iconic landmarks, like Burj Khalifa, and well-known movie titles like Avatar.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: